Female balb c mice

Female BALB/c mice were used (8 weeks old; purchased from Janvier, Saint Berthevin, France). The experiments performed followed the National Animal Protection Guidelines and were approved by the German Animal Ethics Committee for the protection of animals (G0253/14 and G0113/15).

Female BALB/c mice (6–8 weeks, Janvier Laboratories, France) were housed under specific pathogen-free conditions in the animal care facility (Translational animal research center, Mainz) according to the guidelines of the regional animal care committee. All experiments were performed after approval in accordance with federal guidelines.

Female BALB/c mice (8 per group, 6 weeks old; Janvier Labs, Le Genest-Saint-Isle, France) were intravenously infected with 8 × 10⁷ CFU of bacteria via the tail vein. The mice were housed in individually ventilated cages under normal diet in groups of five throughout the experiment with ad libitum access to food and water. During infection, mice were scored twice a day, and the severity of infection (score; see Table S6) was determined accordingly. If a mouse reached the humane endpoint with a score of 20 points, this mouse was sacrificed and removed from the experiment. In this case, the mouse was regarded as dead beginning with this time point in the survival curve (Fig. 2). Significant difference in the survival of the three groups of mice was determined with the Gehan-Breslow-Wilcoxon test (software: GraphPad Prism 5.0).

Female BALB/c mice aged 6-8 weeks (Janvier, le Genest-Saint-Isle, France) were used in all experiments. All experiments involving research animals were pre-approved for ethics by the Norwegian Food Safety Authority. Cell work was performed with human embryonic kidney 293E cells purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Female C57Bl/6 mice were purchased from Taconic Europe A/S (Denmark), and maintained under standardized conditions. Female Balb/c mice were purchased from JANVIER LABS (France). The mice were routinely used at the age of 8 to 12 weeks. All studies were approved by the Bioethics Committee in Lund, Sweden (M60-10 and M450-12), the Bioethics Committee of IPSEN (C2EA-13-048-S1) and by the French ministry (00617.01). All the experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Mice were treated with tasquinimod (30 mg/kg) ad lib. via drinking water or in the case of time studies by p.o. administration. The 4 T1 tumor cells were purchased from ATCC (France). The MC38 tumor cell line was obtained from S. A. Rosenberg (Nat. Cancer Inst., Bethesda, Maryland) and was transfected with the C215 antigen as previously described [52 ]. The cells were cultured in RPMI-1640 supplemented with ultra-glutamine (BioWhittaker/Lonza, Wokingham, UK); 10 % fetal bovine serum (Fisher Scientific, Pittsburgh, PA), 1 mM sodium pyruvate, 10 mM HEPES, 0.2 mg/ml gentamicine sulfate and 50 μM β-mercaptoethanol (R10 medium).

Female BALB/c mice (aged 7–9 weeks) were obtained from Janvier Laboratories (France) and kept under specific pathogen-free conditions. The animal experimental protocols were approved by the ethics committee of the Tübingen Regional Council.